TMCnet News
INVESTOR NOTICE: Khang & Khang LLP Announces an Investigation of Claims against Akebia Therapeutics, Inc. on Behalf of InvestorsKhang & Khang LLP announces that it is investigating claims of potential misrepresentations by Akebia Therapeutics, Inc. ("Akebia" or the "Company") (AKBA). The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors. If you purchased shares of Akebia during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA (News - Alert) 92612, y telephone: (949) 419-3834, or by email at [email protected]. There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member. On October 27, 2014, Akebia reported the results of its Phase 2b Study of oral therapy AKB-6548 in non-dialysis patients with anemia related to chronic kidney disease. The Company cited a "higher incidence of serious adverse events (SAEs) reported in the active treatment group versus the placebo group." If you wish to learn more about this lawsuit, or if you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by email at [email protected]. This press release may constitute Attorney Advertising in some jurisdictions.
View source version on businesswire.com: http://www.businesswire.com/news/home/20151013006987/en/ |
